R. Tandon, M. Keshavan, and H. Nasrallah, Schizophrenia, ???Just the Facts??? What we know in 2008. 2. Epidemiology and etiology, Schizophrenia Research, vol.102, issue.1-3, pp.1-31, 2008.
DOI : 10.1016/j.schres.2008.04.011

J. Smoller, N. Craddock, K. Kendler, P. Lee, and B. Neale, Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis, Lancet. 20 avr, vol.381, issue.9875, pp.1371-1379, 2013.

P. Lichtenstein, B. Yip, C. Björk, Y. Pawitan, T. Cannon et al., Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study, The Lancet, vol.373, issue.9659, pp.234-239, 2009.
DOI : 10.1016/S0140-6736(09)60072-6

N. Craddock and M. Owen, The Kraepelinian dichotomy - going, going... but still not gone, The British Journal of Psychiatry, vol.196, issue.2, pp.92-95, 2010.
DOI : 10.1192/bjp.bp.109.073429

O. Owoeye, T. Kingston, P. Scully, P. Baldwin, D. Browne et al., Epidemiological and Clinical Characterization Following a First Psychotic Episode in Major Depressive Disorder: Comparisons With Schizophrenia and Bipolar I Disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS), Schizophrenia Bulletin, vol.39, issue.4, pp.756-765, 2013.
DOI : 10.1093/schbul/sbt075

M. Cuesta, E. García-de-jalón, M. Campos, B. Ibáñez, A. Sánchez-torres et al., Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis, Schizophrenia Research, vol.141, issue.2-3, pp.2-3222, 2012.
DOI : 10.1016/j.schres.2012.08.019

S. Bender, M. Weisbrod, and F. Resch, Which perspectives can endophenotypes and biological markers offer in the early recognition of schizophrenia?, Journal of Neural Transmission, vol.13, issue.Suppl 2, pp.1199-1215, 2007.
DOI : 10.1007/s00702-007-0742-4

R. Wyatt, Neuroleptics and the Natural Course of Schizophrenia, Schizophrenia Bulletin, vol.17, issue.2, pp.325-351, 1991.
DOI : 10.1093/schbul/17.2.325

R. Yolken and E. Torrey, Are some cases of psychosis caused by microbial agents? A review of the evidence, Molecular Psychiatry, vol.23, issue.5, pp.470-479, 2008.
DOI : 10.1128/AAC.00793-06

J. Van-os, G. Kenis, and B. Rutten, The environment and schizophrenia, Nature, vol.65, issue.7321, pp.203-212, 2010.
DOI : 10.1038/nature09563

E. Torrey, R. Rawlings, and R. Yolken, The antecedents of psychoses: a case???control study of selected risk factors, Schizophrenia Research, vol.46, issue.1, pp.17-23, 2000.
DOI : 10.1016/S0920-9964(99)00237-6

J. Vilain, A. Galliot, J. Durand-roger, M. Leboyer, P. Llorca et al., Les facteurs de risque environnementaux de la schizophr??nie, L'Enc??phale, vol.39, issue.1, pp.19-28, 2013.
DOI : 10.1016/j.encep.2011.12.007

A. Brown, Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism, Developmental Neurobiology, vol.28, issue.10, pp.1272-1276, 2012.
DOI : 10.1002/dneu.22024

R. Parboosing, Y. Bao, L. Shen, C. Schaefer, and A. Brown, Gestational Influenza and Bipolar Disorder in Adult Offspring, JAMA Psychiatry, vol.70, issue.7, pp.677-685, 2013.
DOI : 10.1001/jamapsychiatry.2013.896

A. Brown and E. Derkits, Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies, American Journal of Psychiatry, vol.167, issue.3, pp.261-280, 2010.
DOI : 10.1176/appi.ajp.2009.09030361

E. Torrey, J. Bartko, and R. Yolken, Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update, Schizophrenia Bulletin, vol.38, issue.3, pp.642-647, 2012.
DOI : 10.1093/schbul/sbs043

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329973

N. Hamdani, C. Daban-huard, M. Lajnef, J. Richard, M. Delavest et al., Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample, Journal of Affective Disorders, vol.148, issue.2-3, pp.2-3444, 2013.
DOI : 10.1016/j.jad.2012.11.034

O. Okusaga, R. Yolken, P. Langenberg, M. Lapidus, T. Arling et al., Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts, Journal of Affective Disorders, vol.130, issue.1-2, pp.220-225, 2011.
DOI : 10.1016/j.jad.2010.09.029

F. Dickerson, J. Boronow, C. Stallings, A. Origoni, S. Cole et al., Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder, Biological Psychiatry, vol.55, issue.6, pp.588-593, 2004.
DOI : 10.1016/j.biopsych.2003.10.008

F. Dickerson, B. Kirkpatrick, J. Boronow, C. Stallings, A. Origoni et al., Deficit Schizophrenia: Association With Serum Antibodies to Cytomegalovirus, Schizophrenia Bulletin, vol.32, issue.2, pp.396-400, 2006.
DOI : 10.1093/schbul/sbi054

A. Brown, R. Deicken, S. Vinogradov, W. Kremen, J. Poole et al., Prenatal infection and cavum septum pellucidum in adult schizophrenia, Schizophrenia Research, vol.108, issue.1-3, pp.1-3285, 2009.
DOI : 10.1016/j.schres.2008.11.018

A. Brown, S. Vinogradov, W. Kremen, J. Poole, R. Deicken et al., Prenatal Exposure to Maternal Infection and Executive Dysfunction in Adult Schizophrenia, American Journal of Psychiatry, vol.166, issue.6, pp.683-690, 2009.
DOI : 10.1176/appi.ajp.2008.08010089

J. Houenou, M. Albis, C. Daban, N. Hamdani, M. Delavest et al., Cytomegalovirus seropositivity and serointensity are associated with hippocampal volume and verbal memory in schizophrenia and bipolar disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.48, pp.142-148, 2014.
DOI : 10.1016/j.pnpbp.2013.09.003

URL : https://hal.archives-ouvertes.fr/inserm-00877593

C. Carter, Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii, Schizophrenia Bulletin, vol.35, issue.6, pp.1163-1182, 2009.
DOI : 10.1093/schbul/sbn054

M. Leboyer, R. Tamouza, D. Charron, R. Faucard, and H. Perron, Human endogenous retrovirus type W (HERV-W) in schizophrenia: A new avenue of research at the gene???environment interface, The World Journal of Biological Psychiatry, vol.107, issue.1, pp.80-90, 2013.
DOI : 10.1111/j.1468-1331.2009.02552.x

H. Perron, N. Hamdani, R. Faucard, M. Lajnef, S. Jamain et al., Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder, Translational Psychiatry, vol.38, issue.12, p.201, 2012.
DOI : 10.1038/nm0510-517

URL : https://hal.archives-ouvertes.fr/inserm-00807038

M. Suntsova, E. Gogvadze, S. Salozhin, N. Gaifullin, F. Eroshkin et al., Human-specific endogenous retroviral insert serves as an enhancer for the schizophrenia-linked gene PRODH, Proceedings of the National Academy of Sciences, vol.110, issue.48, 2013.
DOI : 10.1073/pnas.1318172110

H. Stefansson, R. Ophoff, S. Steinberg, O. Andreassen, S. Cichon et al., Common variants conferring risk of schizophrenia, Nature, vol.155, issue.7256, pp.744-747, 2009.
DOI : 10.1038/nature08186

. International-schizophrenia-consortium, S. Purcell, N. Wray, J. Stone, P. Visscher et al., Common polygenic variation contributes to risk of schizophrenia and bipolar disorder, Nature. 6 août, vol.460, issue.7256, pp.748-752, 2009.

S. Mexal, M. Frank, R. Berger, C. Adams, R. Ross et al., Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenic and control smokers, Molecular Brain Research, vol.139, issue.2, pp.317-332, 2005.
DOI : 10.1016/j.molbrainres.2005.06.006

S. Glatt, I. Everall, W. Kremen, J. Corbeil, R. Sásik et al., Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia, Proceedings of the National Academy of Sciences, vol.102, issue.43, pp.15533-15538, 2005.
DOI : 10.1073/pnas.0507666102

P. Saetre, L. Emilsson, E. Axelsson, J. Kreuger, E. Lindholm et al., Inflammation-related genes up-regulated in schizophrenia brains, BMC Psychiatry, vol.64, issue.6, p.46, 2007.
DOI : 10.4088/JCP.v64n0618e

M. Debnath, D. Cannon, and G. Venkatasubramanian, Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: Associations and functional implications, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.42, pp.49-62, 2013.
DOI : 10.1016/j.pnpbp.2012.07.009

L. Fourgeaud, C. Davenport, C. Tyler, T. Cheng, M. Spencer et al., MHC class I modulates NMDA receptor function and AMPA receptor trafficking, Proceedings of the National Academy of Sciences, vol.107, issue.51, pp.22278-22283, 2010.
DOI : 10.1073/pnas.0914064107

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3009822

P. Czerski, F. Rybakowski, P. Kapelski, J. Rybakowski, M. Dmitrzak-weglarz et al., Association of Tumor Necrosis Factor –308G/A Promoter Polymorphism with Schizophrenia and Bipolar Affective Disorder in a Polish Population, Neuropsychobiology, vol.57, issue.1-2, pp.88-94, 2008.
DOI : 10.1159/000135642

A. Altamura, E. Mundo, E. Cattaneo, S. Pozzoli, B. Dell-'osso et al., The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study, Neuroimmunomodulation, vol.17, issue.2, pp.126-131, 2010.
DOI : 10.1159/000258696

R. Zakharyan, A. Boyajyan, A. Arakelyan, M. Melkumova, F. Mrazek et al., Monocyte chemoattractant protein-1 in schizophrenia: ???2518A/G genetic variant and protein levels in Armenian population, Cytokine, vol.58, issue.3, pp.351-354, 2012.
DOI : 10.1016/j.cyto.2012.02.013

J. Oliveira, M. Busson, B. Etain, S. Jamain, N. Hamdani et al., Polymorphism of Toll-like receptor 4 gene in bipolar disorder, Journal of Affective Disorders, vol.152, issue.154, pp.152-154395, 2014.
DOI : 10.1016/j.jad.2013.09.043

M. Debnath, M. Busson, S. Jamain, B. Etain, N. Hamdani et al., The HLA-G low expressor genotype is associated with protection against bipolar disorder, Human Immunology, vol.74, issue.5, pp.593-597, 2013.
DOI : 10.1016/j.humimm.2012.11.032

URL : https://hal.archives-ouvertes.fr/inserm-00864639

B. Goldstein, D. Kemp, J. Soczynska, and R. Mcintyre, Inflammation and the Phenomenology, Pathophysiology, Comorbidity, and Treatment of Bipolar Disorder, The Journal of Clinical Psychiatry, vol.70, issue.8, pp.1078-1090, 2009.
DOI : 10.4088/JCP.08r04505

B. Goldstein, B. Birmaher, D. Axelson, T. Goldstein, C. Esposito-smythers et al., Preliminary Findings Regarding Overweight and Obesity in Pediatric Bipolar Disorder, The Journal of Clinical Psychiatry, vol.69, issue.12, 1953.
DOI : 10.4088/JCP.v69n1215

M. Leboyer, I. Soreca, J. Scott, M. Frye, C. Henry et al., Can bipolar disorder be viewed as a multi-system inflammatory disease?, Journal of Affective Disorders, vol.141, issue.1, pp.1-10, 2012.
DOI : 10.1016/j.jad.2011.12.049

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498820

N. Hepgul, C. Pariante, S. Dipasquale, M. Diforti, H. Taylor et al., Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients, Psychological Medicine, vol.156, issue.09, pp.1893-1901, 2012.
DOI : 10.1016/j.biopsych.2008.05.018

B. Miller, N. Culpepper, and M. Rapaport, C-Reactive Protein Levels in Schizophrenia, Clinical Schizophrenia & Related Psychoses, vol.7, issue.4, 2013.
DOI : 10.3371/CSRP.MICU.020813

F. Dickerson, C. Stallings, A. Origoni, J. Boronow, and R. Yolken, Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.31, issue.4, pp.952-955, 2007.
DOI : 10.1016/j.pnpbp.2007.02.018

M. Maes, J. Delange, R. Ranjan, H. Meltzer, R. Desnyder et al., Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs, Psychiatry Research, vol.66, issue.1, pp.1-11, 1997.
DOI : 10.1016/S0165-1781(96)02915-0

B. Miller, P. Buckley, W. Seabolt, A. Mellor, and B. Kirkpatrick, Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects, Biological Psychiatry, vol.70, issue.7, pp.663-671, 2011.
DOI : 10.1016/j.biopsych.2011.04.013

A. Modabbernia, S. Taslimi, E. Brietzke, and M. Ashrafi, Cytokine Alterations in Bipolar Disorder: A Meta-Analysis of 30 Studies, Biological Psychiatry, vol.74, issue.1, pp.15-25, 2013.
DOI : 10.1016/j.biopsych.2013.01.007

B. Miller, B. Gassama, D. Sebastian, P. Buckley, and A. Mellor, Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects, Biological Psychiatry, vol.73, issue.10, pp.993-999, 2013.
DOI : 10.1016/j.biopsych.2012.09.007

H. Nikkila, K. Müller, A. Ahokas, K. Miettinen, L. Andersson et al., Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia, Schizophrenia Research, vol.14, issue.3, pp.215-221, 1995.
DOI : 10.1016/0920-9964(94)00039-B

¯. Nikkilâ-o, . Hv, K. M�, A. Ahokas, K. Miettinen et al., Accumulation of Macrophages in the CSF of Schizophrenic Patients During Acute Psychotic Episodes, Am J Psychiatry. 1 nov, vol.156, issue.11, pp.1725-1729, 1999.

R. Drexhage, E. Knijff, R. Padmos, L. Heul-nieuwenhuijzen, . Van-der et al., The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder, Expert Review of Neurotherapeutics, vol.10, issue.1, pp.59-76, 2010.
DOI : 10.1586/ern.09.144

M. Tremblay, B. Stevens, A. Sierra, H. Wake, A. Bessis et al., The Role of Microglia in the Healthy Brain, Journal of Neuroscience, vol.31, issue.45, pp.16064-16069, 2011.
DOI : 10.1523/JNEUROSCI.4158-11.2011

A. Kaindl, V. Degos, S. Peineau, E. Gouadon, V. Chhor et al., Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain, Annals of Neurology, vol.43, issue.4, pp.536-549, 2012.
DOI : 10.1002/ana.23626

R. Smith and M. Maes, The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence, Medical Hypotheses, vol.45, issue.2, pp.135-141, 1995.
DOI : 10.1016/0306-9877(95)90062-4

M. Schwarz, N. Müller, M. Riedel, and M. Ackenheil, The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms, Medical Hypotheses, vol.56, issue.4, pp.483-486, 2001.
DOI : 10.1054/mehy.2000.1203

A. Monji, T. Kato, and S. Kanba, Cytokines and schizophrenia: Microglia hypothesis of schizophrenia, Psychiatry and Clinical Neurosciences, vol.12, issue.3, pp.257-265, 2009.
DOI : 10.1111/j.1440-1819.2009.01945.x

A. Ezeoke, A. Mellor, P. Buckley, and B. Miller, A systematic, quantitative review of blood autoantibodies in schizophrenia, Schizophrenia Research, vol.150, issue.1, pp.245-251, 2013.
DOI : 10.1016/j.schres.2013.07.029

N. Rose, Characteristics of Autoimmune Disease, Journal of Investigative Dermatology, vol.96, issue.5, pp.87-87, 1991.
DOI : 10.1111/1523-1747.ep12472162

M. Benros, W. Eaton, and P. Mortensen, The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis, Biological Psychiatry, vol.75, issue.4, pp.300-306, 2014.
DOI : 10.1016/j.biopsych.2013.09.023

A. Henneberg, S. Horter, and S. Ruffert, Increased prevalence of antibrain antibodies in the sera from schizophrenic patients, Schizophrenia Research, vol.14, issue.1, pp.15-22, 1994.
DOI : 10.1016/0920-9964(94)90004-3

J. Saunders and E. Muchmore, Phenothiazine Effect on Human Antibody Synthesis, The British Journal of Psychiatry, vol.110, issue.464, pp.84-89, 1964.
DOI : 10.1192/bjp.110.464.84

L. Jones-brando, E. Torrey, and R. Yolken, Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii, Schizophrenia Research, vol.62, issue.3, pp.237-244, 2003.
DOI : 10.1016/S0920-9964(02)00357-2

D. Goodwin, J. Strobl, and D. Lindsay, Evaluation of Five Antischizophrenic Agents Against Toxoplasma gondii in Human Cell Cultures, Journal of Parasitology, vol.97, issue.1, pp.148-151, 2011.
DOI : 10.1645/GE-2536.1

G. Fond, A. Macgregor, R. Tamouza, N. Hamdani, A. Meary et al., Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate, European Archives of Psychiatry and Clinical Neuroscience, vol.31, issue.2, pp.179-183, 2014.
DOI : 10.1007/s00406-013-0413-4

URL : https://hal.archives-ouvertes.fr/inserm-00844714

J. Amsterdam, G. Maislin, and J. Rybakowski, A possible antiviral action of lithium carbonate in herpes simplex virus infections, Biological Psychiatry, vol.27, issue.4, pp.447-453, 1990.
DOI : 10.1016/0006-3223(90)90555-G

J. Kristiansen, L. Andersen, B. Vestergaard, and E. Hvidberg, Effect of Selected Neuroleptic Agents and Stereo-Isomeric Analogues on Virus and Eukaryotic Cells, Pharmacology & Toxicology, vol.50, issue.No. 12, pp.399-403, 1991.
DOI : 10.1111/j.1600-0773.1991.tb01260.x

V. Tourjman, É. Kouassi, M. Koué, M. Rocchetti, S. Fortin-fournier et al., Antipsychotics' effects on blood levels of cytokines in schizophrenia: a metaanalysis, Schizophr Res. déc, vol.151, pp.1-343, 2013.

M. Rapaport and H. Manji, The effects of lithium on ex vivo cytokine production, Biological Psychiatry, vol.50, issue.3, pp.217-224, 2001.
DOI : 10.1016/S0006-3223(01)01144-1

T. Kato, A. Monji, S. Hashioka, and S. Kanba, Risperidone significantly inhibits interferon-??-induced microglial activation in vitro, Schizophrenia Research, vol.92, issue.1-3, pp.1-3108, 2007.
DOI : 10.1016/j.schres.2007.01.019

S. Bhangle, N. Kramer, and E. Rosenstein, Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus, Rheumatology International, vol.125, issue.suppl, 1923.
DOI : 10.1007/s00296-013-2750-z

T. Goh, R. Dhillon, and T. Bastiampillai, Manic Induction with Interferon Alpha Therapy, Australian & New Zealand Journal of Psychiatry, vol.25, issue.11, p.1004, 2011.
DOI : 10.1038/clpt.1981.154

G. Garcia-parés, C. Domenech, and M. Gil, Psychosis Induced by Interferon-??, Psychosomatics, vol.43, issue.5, pp.428-429, 2002.
DOI : 10.1176/appi.psy.43.5.428

L. Mcgregor, S. Saunders, J. Hunter, and E. Murphy, Acute psychosis in three patients receiving anti-tumour necrosis factor-?? therapy, Rheumatology, vol.47, issue.8, pp.1254-1255, 2008.
DOI : 10.1093/rheumatology/ken212

S. Ij and R. Eh, Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid, Dis Chest. avr, vol.21, issue.4, pp.385-438, 1952.

N. Müller, A. Myint, D. Krause, E. Weidinger, and M. Schwarz, Anti-inflammatory treatment in schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.42, pp.146-153, 2013.
DOI : 10.1016/j.pnpbp.2012.11.008

G. Fond, N. Hamdani, F. Kapczinski, W. Boukouaci, N. Drancourt et al., Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review, Acta Psychiatrica Scandinavica, vol.10, issue.Suppl 3, pp.163-179, 2014.
DOI : 10.1111/acps.12211

N. Müller, M. Ulmschneider, C. Scheppach, M. Schwarz, M. Ackenheil et al., COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy, European Archives of Psychiatry and Clinical Neuroscience, vol.254, issue.1, pp.14-22, 2004.
DOI : 10.1007/s00406-004-0478-1

J. Knight, D. Menkes, J. Highton, and D. Adams, Rationale for a trial of immunosuppressive therapy in acute schizophrenia, Molecular Psychiatry, vol.37, issue.5, pp.424-431, 2007.
DOI : 10.1038/sj.mp.4001959

C. Raison, R. Rutherford, B. Woolwine, C. Shuo, P. Schettler et al., A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression, JAMA Psychiatry, vol.70, issue.1, pp.31-41, 2013.
DOI : 10.1001/2013.jamapsychiatry.4

M. Zandi, S. Irani, B. Lang, P. Waters, P. Jones et al., Disease-relevant autoantibodies in first episode schizophrenia, Journal of Neurology, vol.13, issue.4, pp.686-688, 2011.
DOI : 10.1007/s00415-010-5788-9

L. Kalia, S. Kalia, and M. Salter, NMDA receptors in clinical neurology: excitatory times ahead, The Lancet Neurology, vol.7, issue.8, pp.742-755, 2008.
DOI : 10.1016/S1474-4422(08)70165-0

P. Paoletti, C. Bellone, and Q. Zhou, NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease, Nature Reviews Neuroscience, vol.135, issue.6, pp.383-400, 2013.
DOI : 10.1038/nrn3504

J. Kantrowitz and D. Javitt, N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?, Brain Research Bulletin, vol.83, issue.3-4, pp.3-4108, 2010.
DOI : 10.1016/j.brainresbull.2010.04.006

A. Leonard, K. Bayer, M. Merrill, I. Lim, M. Shea et al., Regulation of Calcium/Calmodulin-dependent Protein Kinase II Docking toN-Methyl-D-aspartate Receptors by Calcium/Calmodulin and ??-Actinin, Journal of Biological Chemistry, vol.277, issue.50, pp.48441-48448, 2002.
DOI : 10.1074/jbc.M205164200

I. Lim, D. Hall, and J. Hell, Selectivity and Promiscuity of the First and Second PDZ Domains of PSD-95 and Synapse-associated Protein 102, Journal of Biological Chemistry, vol.277, issue.24, pp.21697-21711, 2002.
DOI : 10.1074/jbc.M112339200

M. Dalva, M. Takasu, M. Lin, S. Shamah, L. Hu et al., EphB Receptors Interact with NMDA Receptors and Regulate Excitatory Synapse Formation, Cell, vol.103, issue.6, pp.945-956, 2000.
DOI : 10.1016/S0092-8674(00)00197-5

URL : http://doi.org/10.1016/s0092-8674(00)00197-5

B. Moghaddam and D. Javitt, From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment, Neuropsychopharmacology, vol.35, issue.1, pp.4-15, 2012.
DOI : 10.1073/pnas.76.10.5372

J. Kim, H. Kornhuber, W. Schmid-burgk, and B. Holzmüller, Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia, Neuroscience Letters, vol.20, issue.3
DOI : 10.1016/0304-3940(80)90178-0

M. Frye, G. Tsai, T. Huggins, J. Coyle, and R. Post, Low Cerebrospinal Fluid Glutamate and Glycine in Refractory Affective Disorder, Biological Psychiatry, vol.61, issue.2, pp.162-166, 2007.
DOI : 10.1016/j.biopsych.2006.01.024

S. Patil, L. Zhang, F. Martenyi, S. Lowe, K. Jackson et al., Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial, Nature Medicine, vol.43, issue.9, pp.1102-1107, 2007.
DOI : 10.1038/nm1632

V. Stauffer, S. Baygani, B. Kinon, and J. Krikke-workel, A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia, Journal of Clinical Psychopharmacology, vol.34, issue.5, 2014.
DOI : 10.1097/JCP.0000000000000187

S. Begni, S. Moraschi, S. Bignotti, F. Fumagalli, L. Rillosi et al., Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia, Biological Psychiatry, vol.53, issue.7, pp.617-619, 2003.
DOI : 10.1016/S0006-3223(02)01783-3

L. Martucci, A. Wong, D. Luca, V. Likhodi, O. Wong et al., Nmethyl-d-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels, Schizophr Res. juin, vol.84, pp.2-3214, 2006.

N. Allen, S. Bagade, M. Mcqueen, J. Ioannidis, F. Kavvoura et al., Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database, Nature Genetics, vol.315, issue.7, pp.827-834, 2008.
DOI : 10.1177/1740774507079441

S. Qin, X. Zhao, Y. Pan, J. Liu, G. Feng et al., An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray, European Journal of Human Genetics, vol.59, issue.7, pp.807-814, 2005.
DOI : 10.1161/01.CIR.0000124487.36586.26

L. Kristiansen, I. Huerta, M. Beneyto, and J. Meador-woodruff, NMDA receptors and schizophrenia, Current Opinion in Pharmacology, vol.7, issue.1, pp.48-55, 2007.
DOI : 10.1016/j.coph.2006.08.013

F. Iasevoli, C. Tomasetti, E. Buonaguro, and A. De-bartolomeis, The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment, Current Neuropharmacology, vol.12, issue.3, pp.219-238, 2014.
DOI : 10.2174/1570159X12666140324183406

D. Javitt, Glutamate as a therapeutic target in psychiatric disorders, Molecular Psychiatry, vol.9, issue.11, pp.984-997, 2004.
DOI : 10.1038/sj.mp.4001551

H. Lane, C. Lin, M. Green, G. Hellemann, C. Huang et al., Add-on Treatment of Benzoate for Schizophrenia, JAMA Psychiatry, vol.70, issue.12, pp.1267-1275, 2013.
DOI : 10.1001/jamapsychiatry.2013.2159

A. Sreekumar, L. Poisson, T. Rajendiran, A. Khan, Q. Cao et al., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression, Nature, vol.12, issue.7231, pp.910-914, 2009.
DOI : 10.1038/nature07762

E. Pinard, A. Alanine, D. Alberati, M. Bender, E. Borroni et al., )-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia, Journal of Medicinal Chemistry, vol.53, issue.12, pp.4603-4614, 2010.
DOI : 10.1021/jm100210p

D. Umbricht, D. Alberati, M. Martin-facklam, E. Borroni, E. Youssef et al., Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia, JAMA Psychiatry, vol.71, issue.6, pp.637-646, 2014.
DOI : 10.1001/jamapsychiatry.2014.163

D. Bugarski-kirola, A. Wang, D. Abi-saab, and T. Blättler, A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia ??? Results from the CandleLyte study, European Neuropsychopharmacology, vol.24, issue.7, pp.1024-1036, 2014.
DOI : 10.1016/j.euroneuro.2014.03.007

V. Labrie, A. Wong, and J. Roder, Contributions of the d-serine pathway to schizophrenia, Neuropharmacology, vol.62, issue.3, pp.1484-1503, 2012.
DOI : 10.1016/j.neuropharm.2011.01.030

K. Hashimoto, Y. Fujita, M. Horio, S. Kunitachi, M. Iyo et al., Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine, Biological Psychiatry, vol.65, issue.12, pp.1103-1106, 2009.
DOI : 10.1016/j.biopsych.2009.01.002

A. Shih, H. Erb, X. Sun, S. Toda, P. Kalivas et al., Cystine/Glutamate Exchange Modulates Glutathione Supply for Neuroprotection from Oxidative Stress and Cell Proliferation, Journal of Neuroscience, vol.26, issue.41, pp.10514-10523, 2006.
DOI : 10.1523/JNEUROSCI.3178-06.2006

P. Steullet, J. Cabungcal, A. Monin, D. Dwir, O. Donnell et al., Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A ???central hub??? in schizophrenia pathophysiology?, Schizophrenia Research, vol.176, issue.1, 2014.
DOI : 10.1016/j.schres.2014.06.021

I. Sommer, R. Van-westrhenen, M. Begemann, L. De-witte, S. Leucht et al., Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update, Schizophrenia Bulletin, vol.40, issue.1, pp.181-191, 2014.
DOI : 10.1093/schbul/sbt139

N. Spear, R. Gadient, D. Wilkins, M. Do, J. Smith et al., Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator, European Journal of Pharmacology, vol.659, issue.2-3, pp.2-3146, 2011.
DOI : 10.1016/j.ejphar.2011.02.003

S. Parmentier-batteur, O. Brien, J. Doran, S. Nguyen, S. Flick et al., Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration, Neuropharmacology, vol.62, issue.3, pp.1453-1460, 2012.
DOI : 10.1016/j.neuropharm.2010.11.013

S. Parmentier-batteur, P. Hutson, K. Menzel, J. Uslaner, B. Mattson et al., Mechanism based neurotoxicity of mGlu5 positive allosteric modulators ??? Development challenges for a promising novel antipsychotic target, Neuropharmacology, vol.82, pp.161-173, 2014.
DOI : 10.1016/j.neuropharm.2012.12.003

S. Berretta, Extracellular matrix abnormalities in schizophrenia, Neuropharmacology, vol.62, issue.3, pp.1584-1597, 2012.
DOI : 10.1016/j.neuropharm.2011.08.010

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234338

K. Hashimoto, Emerging role of glutamate in the pathophysiology of major depressive disorder, Brain Research Reviews, vol.61, issue.2, pp.105-123, 2009.
DOI : 10.1016/j.brainresrev.2009.05.005

S. Maeng and C. Zarate, The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects, Current Psychiatry Reports, vol.64, issue.Suppl, pp.467-474, 2007.
DOI : 10.1007/s11920-007-0063-1

G. Fond, A. Loundou, C. Rabu, A. Macgregor, C. Lançon et al., Ketamine administration in depressive disorders: a systematic review and metaanalysis . Psychopharmacology (Berl), 2014.

R. Dantzer, O. Connor, J. Freund, G. Johnson, R. Kelley et al., From inflammation to sickness and depression: when the immune system subjugates the brain, Nature Reviews Neuroscience, vol.17, issue.1, pp.46-56, 2008.
DOI : 10.1038/nrn2297

J. Steiner, B. Bogerts, Z. Sarnyai, M. Walter, T. Gos et al., Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood???brain barrier integrity, The World Journal of Biological Psychiatry, vol.15, issue.2, pp.482-492, 2012.
DOI : 10.1038/sj.mp.4000813

R. Schwarcz and C. Hunter, Toxoplasma gondii and Schizophrenia: Linkage Through Astrocyte-Derived Kynurenic Acid?, Schizophrenia Bulletin, vol.33, issue.3, pp.652-653, 2007.
DOI : 10.1093/schbul/sbm030

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526138

S. Erhardt, K. Blennow, C. Nordin, E. Skogh, L. Lindström et al., Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia, Neuroscience Letters, vol.313, issue.1-2, pp.96-98, 2001.
DOI : 10.1016/S0304-3940(01)02242-X

L. Nilsson, K. Linderholm, G. Engberg, L. Paulson, K. Blennow et al., Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia, Schizophrenia Research, vol.80, issue.2-3, pp.2-3315, 2005.
DOI : 10.1016/j.schres.2005.07.013

A. Myint, Y. Kim, R. Verkerk, S. Scharpé, H. Steinbusch et al., Kynurenine pathway in major depression: Evidence of impaired neuroprotection, Journal of Affective Disorders, vol.98, issue.1-2, pp.143-151, 2007.
DOI : 10.1016/j.jad.2006.07.013

C. Raison, R. Dantzer, K. Kelley, M. Lawson, B. Woolwine et al., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-??: relationship to CNS immune responses and depression, Molecular Psychiatry, vol.1, issue.4, pp.393-403, 2010.
DOI : 10.1016/S0893-133X(01)00407-9

J. Dalmau, E. Tüzün, H. Wu, J. Masjuan, J. Rossi et al., -methyl-D-aspartate receptor encephalitis associated with ovarian teratoma, Annals of Neurology, vol.127, issue.1, pp.25-36, 2007.
DOI : 10.1002/ana.21050

URL : https://hal.archives-ouvertes.fr/hal-00408663

J. Brierley, J. A. Corsellis, R. Hierons, and N. S. , SUBACUTE ENCEPHALITIS OF LATER ADULT LIFE. MAINLY AFFECTING THE LIMBIC AREAS, Brain, vol.83, issue.3, pp.357-368, 1960.
DOI : 10.1093/brain/83.3.357

J. A. Corsellis, G. Goldberg, and A. Norton, ???LIMBIC ENCEPHALITIS??? AND ITS ASSOCIATION WITH CARCINOMA, Brain, vol.91, issue.3, pp.481-496, 1968.
DOI : 10.1093/brain/91.3.481

E. Bickerstaff and P. Cloake, Mesencephalitis and Rhombencephalitis, BMJ, vol.2, issue.4723, pp.77-81, 1951.
DOI : 10.1136/bmj.2.4723.77

A. Merwick, J. Dalmau, and N. Delanty, Insights into antibody-associated encephalitis ??? Bickerstaff's 1950's papers revisited, Journal of the Neurological Sciences, vol.334, issue.1-2, 2013.
DOI : 10.1016/j.jns.2013.07.010

F. Graus, A. Saiz, and J. Dalmau, Antibodies and neuronal autoimmune disorders of the CNS, Journal of Neurology, vol.66, issue.Suppl 13, pp.509-517, 2010.
DOI : 10.1007/s00415-009-5431-9

R. Vitaliani, W. Mason, B. Ances, T. Zwerdling, Z. Jiang et al., Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma, Annals of Neurology, vol.365, issue.4, pp.594-604, 2005.
DOI : 10.1002/ana.20614

J. Dalmau, A. Gleichman, E. Hughes, J. Rossi, X. Peng et al., Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, The Lancet Neurology, vol.7, issue.12, pp.1091-1098, 2008.
DOI : 10.1016/S1474-4422(08)70224-2

J. Granerod, H. Ambrose, N. Davies, J. Clewley, A. Walsh et al., Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study, The Lancet Infectious Diseases, vol.10, issue.12, pp.835-879, 2010.
DOI : 10.1016/S1473-3099(10)70222-X

M. Lai, M. Huijbers, E. Lancaster, F. Graus, L. Bataller et al., Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series, The Lancet Neurology, vol.9, issue.8, pp.776-785, 2010.
DOI : 10.1016/S1474-4422(10)70137-X

S. Irani, A. S. Waters, P. Kleopa, K. Pettingill, P. Zuliani et al., Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia, Brain, vol.133, issue.9, pp.2734-2748, 2010.
DOI : 10.1093/brain/awq213

M. Lai, E. Hughes, X. Peng, L. Zhou, A. Gleichman et al., AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location, Annals of Neurology, vol.7, issue.pt 7, pp.424-434, 2009.
DOI : 10.1002/ana.21589

E. Lancaster, E. Martinez-hernandez, M. Titulaer, M. Boulos, S. Weaver et al., Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome, Neurology, vol.77, issue.18, pp.1698-701, 2011.
DOI : 10.1212/WNL.0b013e3182364a44

E. Lancaster, M. Lai, X. Peng, E. Hughes, R. Constantinescu et al., Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen, The Lancet Neurology, vol.9, issue.1, pp.67-76, 2010.
DOI : 10.1016/S1474-4422(09)70324-2

N. Mas, A. Saiz, M. Leite, P. Waters, M. Baron et al., Antiglycine-receptor encephalomyelitis with rigidity, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.12, pp.1399-1401, 2011.
DOI : 10.1136/jnnp.2010.229104

URL : http://jnnp.bmj.com/cgi/content/short/82/12/1399

M. Gable, H. Sheriff, J. Dalmau, D. Tilley, and C. Glaser, The Frequency of Autoimmune N-Methyl-D-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young Individuals Enrolled in the California Encephalitis Project, Clinical Infectious Diseases, vol.54, issue.7, pp.899-904, 2012.
DOI : 10.1093/cid/cir1038

M. Titulaer, L. Mccracken, I. Gabilondo, T. Armangué, C. Glaser et al., Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study, The Lancet Neurology, vol.12, issue.2, pp.157-165, 2013.
DOI : 10.1016/S1474-4422(12)70310-1

J. Dalmau, E. Lancaster, E. Martinez-hernandez, M. Rosenfeld, and R. Balice-gordon, Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis, The Lancet Neurology, vol.10, issue.1, pp.63-74, 2011.
DOI : 10.1016/S1474-4422(10)70253-2

J. Dalmau, A. Gleichman, E. Hughes, J. Rossi, X. Peng et al., Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies, The Lancet Neurology, vol.7, issue.12, pp.1091-1098, 2008.
DOI : 10.1016/S1474-4422(08)70224-2

J. Caplan, T. Binius, V. Lennon, S. Pittock, and M. Rao, Pseudopseudoseizures: Conditions That May Mimic Psychogenic Non-Epileptic Seizures, Psychosomatics, vol.52, issue.6, pp.501-506, 2011.
DOI : 10.1016/j.psym.2011.08.004

M. Lamarque, D. Psimaras, F. Ducray, I. Pelieu, R. Sonneville et al., Encéphalites auto-immunes à anticorps anti-récepteurs NMDA, une cause fréquente d'encéphalite en réanimation. Réanimation SRLF, 2011.
DOI : 10.1007/s13546-011-0275-6

M. Kayser, M. Titulaer, N. Gresa-arribas, and J. Dalmau, -Aspartate Receptor Encephalitis, JAMA Neurology, vol.70, issue.9, pp.1133-1139, 2013.
DOI : 10.1001/jamaneurol.2013.3216

URL : https://hal.archives-ouvertes.fr/hal-00504990

D. Capua, D. García-ptacek, S. García-garcía, M. Abarrategui, B. Porta-etessam et al., Extreme delta brush in a patient with anti-NMDAR encephalitis, Epileptic Disord Int Epilepsy J Videotape. déc, vol.15, issue.4, pp.461-464, 2013.

T. Iizuka, S. Yoshii, S. Kan, J. Hamada, J. Dalmau et al., Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study, Journal of Neurology, vol.30, issue.10, pp.1686-1691, 2010.
DOI : 10.1007/s00415-010-5604-6

H. Kataoka, J. Dalmau, T. Taoka, and S. Ueno, -acetylaspartate in the basal ganglia of a patient with anti-NMDA receptor encephalitis, Movement Disorders, vol.880, issue.5, pp.784-786, 2009.
DOI : 10.1002/mds.22167

URL : https://hal.archives-ouvertes.fr/in2p3-00461069

T. Iizuka, F. Sakai, T. Ide, T. Monzen, S. Yoshii et al., Anti-NMDA receptor encephalitis in Japan: Long-term outcome without tumor removal, Neurology, vol.70, issue.7, pp.504-511, 2008.
DOI : 10.1212/01.wnl.0000278388.90370.c3

S. Pillai, D. Gill, R. Webster, R. Howman-giles, and R. Dale, Cortical Hypometabolism Demonstrated by PET in Relapsing NMDA Receptor Encephalitis, Pediatric Neurology, vol.43, issue.3, pp.217-220, 2010.
DOI : 10.1016/j.pediatrneurol.2010.04.019

M. Maeder-ingvar, J. Prior, S. Irani, V. Rey, A. Vincent et al., FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.2, pp.235-236, 2011.
DOI : 10.1136/jnnp.2009.198697

V. Llorens, I. Gabilondo, J. Gómez-esteban, M. Agundez, M. Mendibe et al., Abnormal multifocal cerebral blood flow on Tc-99m HMPAO SPECT in a patient with anti-NMDA-receptor encephalitis, Journal of Neurology, vol.3, issue.9, pp.1568-1569, 2010.
DOI : 10.1007/s00415-010-5546-z

N. Gresa-arribas, M. Titulaer, A. Torrents, E. Aguilar, L. Mccracken et al., Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study, The Lancet Neurology, vol.13, issue.2, pp.167-177, 2014.
DOI : 10.1016/S1474-4422(13)70282-5

E. Kozora, S. West, S. Maier, C. Filley, D. Arciniegas et al., Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes, Journal of the Neurological Sciences, vol.295, issue.1-2, pp.87-91, 2010.
DOI : 10.1016/j.jns.2010.04.016

A. Kumakura, T. Miyajima, T. Fujii, Y. Takahashi, and M. Ito, A patient with epilepsia partialis continua with anti-glutamate receptor ??2 antibodies, Pediatric Neurology, vol.29, issue.2, pp.160-163, 2003.
DOI : 10.1016/S0887-8994(03)00151-6

Y. Takahashi, H. Mori, M. Mishina, M. Watanabe, N. Kondo et al., Autoantibodies and Cell-mediated Autoimmunity to NMDA-type GluRe2 in Patients with Rasmussen's Encephalitis and Chronic Progressive Epilepsia Partialis Continua, Epilepsia, vol.13, issue.s5, pp.152-158, 2005.
DOI : 10.1002/ana.10100

J. Deakin, B. Lennox, and M. Zandi, Antibodies to the N-Methyl-D-Aspartate Receptor and Other Synaptic Proteins in Psychosis, Biological Psychiatry, vol.75, issue.4, pp.284-291, 2014.
DOI : 10.1016/j.biopsych.2013.07.018

G. Mackay, K. Ahmad, J. Stone, C. Sudlow, D. Summers et al., NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease, Journal of Neurology, vol.59, issue.9, 1979.
DOI : 10.1007/s00415-012-6489-3

H. Braakman, V. Moers-hornikx, B. Arts, R. Hupperts, and J. Nicolai, Pearls & Oy-sters: Electroconvulsive therapy in anti-NMDA receptor encephalitis, Neurology, vol.75, issue.10, pp.44-46, 2010.
DOI : 10.1212/WNL.0b013e3181f11dc1

C. Hammer, B. Stepniak, A. Schneider, S. Papiol, M. Tantra et al., Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity, Mol Psychiatry, 2013.

T. Blanpied, R. Clarke, and J. Johnson, Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block, Journal of Neuroscience, vol.25, issue.13, pp.3312-3322, 2005.
DOI : 10.1523/JNEUROSCI.4262-04.2005

M. Gable, S. Gavali, A. Radner, D. Tilley, B. Lee et al., Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis, European Journal of Clinical Microbiology & Infectious Diseases, vol.66, issue.1, pp.1421-1429, 2009.
DOI : 10.1007/s10096-009-0799-0

H. Prüss, C. Finke, M. Höltje, J. Hofmann, C. Klingbeil et al., -aspartate receptor antibodies in herpes simplex encephalitis, Annals of Neurology, vol.10, issue.6, pp.902-911, 2012.
DOI : 10.1002/ana.23689

F. Leypoldt, M. Titulaer, E. Aguilar, J. Walther, M. Bönstrup et al., Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report, Neurology, vol.81, issue.18, pp.1637-1639, 2013.
DOI : 10.1212/WNL.0b013e3182a9f531

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806918

R. Höftberger, T. Armangue, F. Leypoldt, F. Graus, and J. Dalmau, Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem, Clinical Neuropathology, vol.32, issue.07, pp.251-254, 2013.
DOI : 10.5414/NP300666

E. Moscato, A. Jain, X. Peng, E. Hughes, J. Dalmau et al., Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies, European Journal of Neuroscience, vol.36, issue.202, pp.298-309, 2010.
DOI : 10.1111/j.1460-9568.2010.07349.x

J. Huber, K. Witt, S. Hom, R. Egleton, K. Mark et al., Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression, Am J Physiol Heart Circ Physiol. mars, vol.280, issue.3, pp.1241-1248, 2001.

A. Rabchevsky, J. Degos, and P. Dreyfus, Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood???brain barrier without inducing reactive gliosis, Brain Research, vol.832, issue.1-2, pp.84-96, 1999.
DOI : 10.1016/S0006-8993(99)01479-1

P. Esposito, N. Chandler, K. Kandere, S. Basu, S. Jacobson et al., Corticotropin-Releasing Hormone and Brain Mast Cells Regulate Blood-Brain-Barrier Permeability Induced by Acute Stress, Journal of Pharmacology and Experimental Therapeutics, vol.303, issue.3, pp.1061-1066, 2002.
DOI : 10.1124/jpet.102.038497

P. Huerta, C. Kowal, L. Degiorgio, B. Volpe, and D. B. , Immunity and behavior: Antibodies alter emotion, Proceedings of the National Academy of Sciences, vol.103, issue.3, pp.678-683, 2006.
DOI : 10.1073/pnas.0510055103

E. Neuwelt, P. Barnett, I. Hellström, K. Hellström, P. Beaumier et al., Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption, Cancer Res. 1 sept, vol.48, issue.17, pp.4725-4729, 1988.

E. Hughes, X. Peng, A. Gleichman, M. Lai, L. Zhou et al., Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis, Journal of Neuroscience, vol.30, issue.17, pp.5866-5875, 2010.
DOI : 10.1523/JNEUROSCI.0167-10.2010

L. Mikasova, D. Rossi, P. Bouchet, D. Georges, F. Rogemond et al., Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis, Brain, vol.135, issue.5, pp.1606-1621, 2012.
DOI : 10.1093/brain/aws092

URL : https://hal.archives-ouvertes.fr/hal-01160045

Q. Zhang, K. Tanaka, P. Sun, M. Nakata, R. Yamamoto et al., Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients, Neurobiology of Disease, vol.45, issue.1, pp.610-615, 2012.
DOI : 10.1016/j.nbd.2011.09.019

R. Petralia, Y. Wang, and R. Wenthold, Internalization at glutamatergic synapses during development, European Journal of Neuroscience, vol.267, issue.12, pp.3207-3217, 2003.
DOI : 10.1016/S0896-6273(00)81066-1

A. Triller and D. Choquet, Surface trafficking of receptors between synaptic and extrasynaptic membranes: and yet they do move!, Trends in Neurosciences, vol.28, issue.3, pp.133-139, 2005.
DOI : 10.1016/j.tins.2005.01.001

J. Henderson, J. Georgiou, Z. Jia, J. Robertson, S. Elowe et al., The Receptor Tyrosine Kinase EphB2 Regulates NMDA-Dependent Synaptic Function, Neuron, vol.32, issue.6, pp.1041-1056, 2001.
DOI : 10.1016/S0896-6273(01)00553-0

M. Nolt, Y. Lin, M. Hruska, J. Murphy, S. Sheffler-colins et al., EphB Controls NMDA Receptor Function and Synaptic Targeting in a Subunit-Specific Manner, Journal of Neuroscience, vol.31, issue.14, pp.5353-5364, 2011.
DOI : 10.1523/JNEUROSCI.0282-11.2011

T. Pollak, R. Mccormack, M. Peakman, T. Nicholson, and A. David, Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis, Psychological Medicine, vol.7, issue.12, 2013.
DOI : 10.1038/npp.2010.163

K. Wandinger, S. Saschenbrecker, W. Stoecker, and J. Dalmau, Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis, Journal of Neuroimmunology, vol.231, issue.1-2, pp.86-91, 2011.
DOI : 10.1016/j.jneuroim.2010.09.012

J. Masdeu, A. González-pinto, C. Matute, R. De-azúa, S. Palomino et al., Subunit of the NMDA Receptor Not Detected in Schizophrenia, American Journal of Psychiatry, vol.169, issue.10, pp.1120-1121, 2012.
DOI : 10.1176/appi.ajp.2012.12050646

C. Creten, S. Van-der-zwaan, R. Blankespoor, A. Maatkamp, J. Nicolai et al., Late onset autism and anti-NMDA-receptor encephalitis, The Lancet, vol.378, issue.9785, p.98, 2011.
DOI : 10.1016/S0140-6736(11)60548-5

. Anti-n-methyl-d-aspartate, NMDA) receptor encephalitis: an unusual cause of autistic regression in a toddler, J Child Neurol. mai, vol.29, issue.5, pp.691-694, 2014.

C. Choe, E. Karamatskos, B. Schattling, F. Leypoldt, G. Liuzzi et al., A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder, Psychiatry Research, vol.208, issue.2, pp.194-196, 2013.
DOI : 10.1016/j.psychres.2012.09.035

J. Steiner, M. Walter, and W. Glanz, Increased Prevalence of Diverse N -Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of Schizophrenia, JAMA Psychiatry, vol.70, issue.3, pp.271-278, 2013.
DOI : 10.1001/2013.jamapsychiatry.86

K. Tsutsui, T. Kanbayashi, K. Tanaka, S. Boku, W. Ito et al., Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features, BMC Psychiatry, vol.61, issue.10, p.37, 2012.
DOI : 10.1016/S0169-328X(98)00211-3

S. Busse, M. Busse, B. Brix, C. Probst, A. Genz et al., Seroprevalence of n-methyl-d-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients, European Archives of Psychiatry and Clinical Neuroscience, vol.35, issue.2
DOI : 10.1007/s00406-014-0493-9

H. Prüss, M. Höltje, N. Maier, A. Gomez, R. Buchert et al., IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment, Neurology, vol.78, issue.22, pp.1743-1753, 2012.
DOI : 10.1212/WNL.0b013e318258300d

M. Lauvsnes and R. Omdal, Systemic lupus erythematosus, the brain, and anti-NR2 antibodies, Journal of Neurology, vol.54, issue.10, pp.622-629, 2012.
DOI : 10.1007/s00415-011-6232-5

R. Omdal, K. Brokstad, K. Waterloo, W. Koldingsnes, R. Jonsson et al., Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors, European Journal of Neurology, vol.41, issue.5, pp.392-398, 2005.
DOI : 10.1038/373151a0

F. Dickerson, C. Stallings, C. Vaughan, A. Origoni, S. Khushalani et al., Antibodies to the glutamate receptor in mania, Bipolar Disorders, vol.16, issue.5, pp.547-53, 2012.
DOI : 10.1111/j.1399-5618.2012.01028.x

F. Dickerson, C. Stallings, A. Origoni, C. Vaughan, E. Katsafanas et al., A Combined Marker of Inflammation in Individuals with Mania, PLoS ONE, vol.494, issue.9, p.73520, 2013.
DOI : 10.1371/journal.pone.0073520.t002

S. Potvin, E. Stip, A. Sepehry, A. Gendron, R. Bah et al., Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review, Biological Psychiatry, vol.63, issue.8, pp.801-808, 2008.
DOI : 10.1016/j.biopsych.2007.09.024

K. Bechter, Updating the mild encephalitis hypothesis of schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.42, pp.71-91, 2013.
DOI : 10.1016/j.pnpbp.2012.06.019

M. Titulaer and J. Dalmau, Antibodies to NMDA receptor, blood???brain barrier disruption and schizophrenia: a theory with unproven links, Molecular Psychiatry, vol.253, issue.10, 2014.
DOI : 10.1016/S1474-4422(13)70282-5

S. Najjar, D. Pearlman, K. Alper, A. Najjar, and O. Devinsky, Neuroinflammation and psychiatric illness, Journal of Neuroinflammation, vol.31, issue.1, p.43, 2013.
DOI : 10.1186/1742-2094-10-43

URL : http://doi.org/10.1186/1742-2094-10-43

A. Vincent, C. Bien, S. Irani, and P. Waters, Autoantibodies associated with diseases of the CNS: new developments and future challenges, The Lancet Neurology, vol.10, issue.8, pp.759-772, 2011.
DOI : 10.1016/S1474-4422(11)70096-5